199 related articles for article (PubMed ID: 17700603)
1. Multiple cycles of PBPC-supported high-dose carboplatin and paclitaxel following mobilization with epirubicin and cisplatin are feasible but ineffective in treating patients with advanced non-small cell lung cancer.
De Giorgi U; Rosti G; Ciucci G; Kopf B; Minzi C; Argnani M; Marangolo M
Bone Marrow Transplant; 2007 Oct; 40(8):735-9. PubMed ID: 17700603
[TBL] [Abstract][Full Text] [Related]
2. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer.
Socinski MA; Shea TC
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-45-S12-51. PubMed ID: 9331121
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: the experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party.
De Giorgi U; Blaise D; Lange A; Viens P; Marangolo M; Madroszyk A; Brune M; Afanassiev BV; Rosti G; Demirer T
Bone Marrow Transplant; 2007 Dec; 40(11):1045-8. PubMed ID: 17922037
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
7. Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer.
Brugger W; Fetscher S; Hasse J; Frommhold H; Pressler K; Mertelsmann R; Engelhardt R; Kanz L
Semin Oncol; 1998 Feb; 25(1 Suppl 2):42-8. PubMed ID: 9535211
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Prince HM; Gardyn J; Millward MJ; Rischin D; Francis P; Gates P; Chapple P; Quinn M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P; Brettell M; Toner GC
Bone Marrow Transplant; 1999 Mar; 23(5):427-35. PubMed ID: 10100555
[TBL] [Abstract][Full Text] [Related]
9. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer.
Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R
Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
11. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer.
Wandt H; Birkmann J; Denzel T; Schäfer K; Schwab G; Pilz D; Egger H; Both A; Gallmeier WM
Bone Marrow Transplant; 1999 Apr; 23(8):763-70. PubMed ID: 10231137
[TBL] [Abstract][Full Text] [Related]
12. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
Charoentum C; Thongprasert S; Chewasakulyong B
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1603-7. PubMed ID: 17940374
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
[TBL] [Abstract][Full Text] [Related]
15. High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer.
De Giorgi U; Rosti G; Zaniboni A; Ballardini M; Minzi MR; Baioni M; Ferrari E; Zornetta L; Marangolo M
Bone Marrow Transplant; 2003 Aug; 32(3):251-5. PubMed ID: 12858195
[TBL] [Abstract][Full Text] [Related]
16. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.
Tell R; Sederholm C; Klintenberg C; Franksson L; Brandén E; Hillerdal G; Lönn U; Lindén CJ; Ewers SB; Lamberg K; Mrazek E; Lödén B; Sjögren A; Linné T; Friesland S; Sirzén F
Anticancer Res; 2008; 28(5B):2851-7. PubMed ID: 19031924
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of epirubicin/paclitaxel combination in mobilizing large amounts of hematopoietic progenitor cells in patients with metastatic breast cancer showing optimal response to the same chemotherapy regimen.
Zibera C; Pedrazzoli P; Ponchio L; Gibelli N; Lanza A; Da Prada GA; Zambelli A; Perotti C; Torretta L; Salvaneschi L; Robustelli della Cuna G
Haematologica; 1999 Oct; 84(10):924-9. PubMed ID: 10509041
[TBL] [Abstract][Full Text] [Related]
18. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
[TBL] [Abstract][Full Text] [Related]
19. Mobilization, collection, and characterization of peripheral blood hemopoietic progenitors after chemotherapy with epirubicin, paclitaxel, and granulocyte-colony stimulating factor administered to patients with metastatic breast carcinoma.
Bengala C; Pazzagli I; Tibaldi C; Favre C; Vanacore R; Greco F; Mazzoni A; Menconi MC; Macchia P; Conte PF
Cancer; 1998 Mar; 82(5):867-73. PubMed ID: 9486575
[TBL] [Abstract][Full Text] [Related]
20. [Comparision of high dose impulsion and low dose density chemotherapeutic regimens with paclitaxel plus cisplatin in advanced NSCLC].
Hua XM; Ren XW; Liu FL; Liu Y; Zhang CJ; Li ZJ; Xu L; Liu JY; Liu YG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):621-5. PubMed ID: 15634526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
